Definitions, measurement, and reporting of progression-free survival in randomized clinical trials and observational studies of patients with advanced non-small-cell lung cancer treated with immunotherapy: a scoping review

M.V. Verschueren , V.P. Tassopoulou , R. Visscher , J. Schuurkamp , B.J.M. Peters , M. Koopman , E.M.W. van de Garde , A.C.G. Egberts , L.T. Bloem
{"title":"Definitions, measurement, and reporting of progression-free survival in randomized clinical trials and observational studies of patients with advanced non-small-cell lung cancer treated with immunotherapy: a scoping review","authors":"M.V. Verschueren ,&nbsp;V.P. Tassopoulou ,&nbsp;R. Visscher ,&nbsp;J. Schuurkamp ,&nbsp;B.J.M. Peters ,&nbsp;M. Koopman ,&nbsp;E.M.W. van de Garde ,&nbsp;A.C.G. Egberts ,&nbsp;L.T. Bloem","doi":"10.1016/j.esmorw.2025.100118","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Evidence from observational studies is increasingly used in oncology to complement evidence from clinical trials. Commonly used endpoints to evaluate oncology medicines are overall survival (OS) and progression-free survival (PFS). However, comparing PFS across observational studies and with clinical trials can be challenging due to differences in its definition and measurement. This scoping review investigated how PFS was defined, measured, and reported in randomized clinical trials (RCTs) and observational studies of patients with advanced non-small-cell lung cancer (NSCLC) treated with immunotherapy.</div></div><div><h3>Materials and methods</h3><div>This scoping review included RCTs and observational studies that measured PFS in advanced NSCLC patients treated with immunotherapy. ASReview, an open-source artificial intelligence-assisted tool, was used to screen and prioritize relevant studies from records identified from PubMed and Embase between 2012 and 2023. Information on study characteristics, PFS definitions, and measurements was extracted.</div></div><div><h3>Results</h3><div>Forty RCTs and 144 observational studies were included. Most RCTs were conducted across multiple continents (70%), while most observational studies were conducted in Asia (62%). In contrast to RCTs, many observational studies lacked reporting on the end date of PFS measurement (69%), the type of radiological imaging (59%), and the imaging reviewer (78%). For observational studies that did report on PFS definitions and measurements, these often differed from those in RCTs, particularly regarding event definitions, the start and stop dates for PFS measurement, and tumor assessment schedules.</div></div><div><h3>Conclusions</h3><div>In contrast to RCTs, observational studies often lack reporting on PFS definitions and measurements, and if reported, they differ across observational studies and between them and RCTs. Since observational studies are important for complementing evidence, aligning PFS definition and measurement criteria with those used in RCTs, along with detailed reporting, is needed. However, some variability in PFS measurement characteristics is unavoidable, and therefore, PFS estimates from observational studies should be interpreted critically and carefully.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"7 ","pages":"Article 100118"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESMO Real World Data and Digital Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949820125000074","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Evidence from observational studies is increasingly used in oncology to complement evidence from clinical trials. Commonly used endpoints to evaluate oncology medicines are overall survival (OS) and progression-free survival (PFS). However, comparing PFS across observational studies and with clinical trials can be challenging due to differences in its definition and measurement. This scoping review investigated how PFS was defined, measured, and reported in randomized clinical trials (RCTs) and observational studies of patients with advanced non-small-cell lung cancer (NSCLC) treated with immunotherapy.

Materials and methods

This scoping review included RCTs and observational studies that measured PFS in advanced NSCLC patients treated with immunotherapy. ASReview, an open-source artificial intelligence-assisted tool, was used to screen and prioritize relevant studies from records identified from PubMed and Embase between 2012 and 2023. Information on study characteristics, PFS definitions, and measurements was extracted.

Results

Forty RCTs and 144 observational studies were included. Most RCTs were conducted across multiple continents (70%), while most observational studies were conducted in Asia (62%). In contrast to RCTs, many observational studies lacked reporting on the end date of PFS measurement (69%), the type of radiological imaging (59%), and the imaging reviewer (78%). For observational studies that did report on PFS definitions and measurements, these often differed from those in RCTs, particularly regarding event definitions, the start and stop dates for PFS measurement, and tumor assessment schedules.

Conclusions

In contrast to RCTs, observational studies often lack reporting on PFS definitions and measurements, and if reported, they differ across observational studies and between them and RCTs. Since observational studies are important for complementing evidence, aligning PFS definition and measurement criteria with those used in RCTs, along with detailed reporting, is needed. However, some variability in PFS measurement characteristics is unavoidable, and therefore, PFS estimates from observational studies should be interpreted critically and carefully.
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信